🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

86 results for “Eye” Clear

  1. VEGF Trap-Eye (BAY86-5321)

    Regeneron UK Limited

    Macular Edema

    phase 3 mab completed

    1 trial

  2. VEGF Trap-Eye 2.0mg

    Regeneron UK Limited

    Macular Edema Secondary to Central Retinal Vein Occlusion

    phase 3 mab completed

    1 trial

  3. VRDN (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor with half-life extension), TED SC Placebo

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  4. VRDN (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor with half-life extension), TED SC Placebo

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  5. VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor)

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  6. VRDN-001 10 mg/kg

    Viridian Pharma Ltd

    Thyroid Eye Disease

    phase 3 small molecule completed

    1 trial

  7. VRDN-001 Phase 3 Cohort (THRIVE)

    Viridian Pharma Ltd

    Thyroid Eye Disease

    phase 3 small molecule completed

    1 trial

  8. VRDN-003

    Viridian Pharma Ltd

    Thyroid Eye Disease (TED)

    phase 3 small molecule active

    1 trial

  9. VRDN-003

    Viridian Pharma Ltd

    Thyroid Eye Disease

    phase 3 small molecule active

    3 trials

  10. Veligrotug

    Viridian Pharma Ltd

    Thyroid Eye Disease

    phase 3 small molecule completed

    1 trial

  11. Veligrotug (VRDN-001)

    Viridian Pharma Ltd

    Thyroid Eye Disease

    phase 3 small molecule completed

    1 trial

  12. Vyvgart 1 000 mg solution for injection in pre-filled syringe, Placebo for efgartigimod

    argenx

    Thyroid Eye Disease (TED)

    phase 3 small molecule active

    1 trial

  13. Wumeiwan Jiawei Fang

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Dry Eye Syndromes

    phase 3 small molecule active

    1 trial

  14. ADX-102 Ophthalmic Solution (0.5%)

    Aldeyra Therapeutics

    Dry Eye Syndromes

    phase 2 small molecule completed

    1 trial

  15. AMG 732

    Amgen

    Thyroid Eye Disease

    phase 2 small molecule active

    1 trial

  16. AU-011

    Aura Biosciences

    Eye Cancer

    phase 2 small molecule active

    1 trial

  17. Alphagan 2 mg/ml colirio en solución, Brimonidine Tartrate 0.2% w/v Eye Drops., Mirvetuximab Soravtansine, Pred Forte 10 mg/ml colirio en suspensión, Pred Forte 1% w/v, Eye Drops Suspension

    AbbVie Deutschland GmbH & Co. KG

    Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression

    phase 2 small molecule active

    1 trial

  18. Atropine Sulfate 0.025% Eye Drops, solution in single-dose container, Atropine Sulfate 0.005% Eye Drops, solution in single-dose container, Placebo Atropine Sulfate Eye Drops, solution in single-dose container, Atropine Sulfate 0.01% Eye Drops, solution in single-dose container, Atropine Sulfate 0.05% Eye Drops, solution in single-dose container

    Lacuna Pharma Pty Ltd

    Myopia progression in children

    phase 2 small molecule active

    1 trial

  19. Hydroxypropyl Guar Galactomannan

    Alcon Laboratories (Australia) Pty Ltd

    Dry Eye Disease

    phase 2 small molecule completed

    1 trial

  20. KIO-101

    KIORA PHARMACEUTICALS INC

    Dry Eye Disease

    phase 2 small molecule terminated

    1 trial

  21. L-Histidine, L-Histidine monohydrochloride monohydrate, Mannitol, Sucrose, Disodium EDTA dihydrate, Polysorbate 80, Water for injection

    Tour Hekla

    Thyroid Eye Disease

    phase 2 small molecule active

    1 trial

  22. Lifitegrast

    Takeda

    Dry Eye

    phase 2 small molecule completed

    1 trial

  23. Methylhydroxypropylcellulose

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Dry Eye Disease

    phase 2 small molecule active

    1 trial

  24. Piromelatine (Neu-P11)

    Lacuna Pharma Pty Ltd

    idiopathic (isolated) Rapid Eye Movement Behavior Disorder

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources